Cogstate Joins New Collaborative of Global Healthcare Leaders to Define Core Digital Measures for Alzheimer’s Disease

June 20, 2022

Neuroscience technology company Cogstate Ltd. (ASX.CGS), today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project. Cogstate joins other DiMe partners including Biogen, Eli Lilly, Eisai, Merck, the Alzheimer’s Drug Discovery Foundation (ADDF) and many others all with the shared objectives to define digital health measurement to speed the development of new therapies and improve care management for patients and families impacted by Alzheimer’s Disease (AD).

AD is a growing public health epidemic, with 47 million people impacted and cases expected to double every 20 years. The costs to individuals, families, and society are staggering. Increasingly, digital tools have the potential to provide more objective and accurate insights about the impact of dementia-related diseases on patients and to better evaluate the effects of therapeutic interventions.

DiMe has convened a project team of global leaders to define a core digital measure set in ADRD to bring consensus, consistency, and effectiveness to how the symptoms of ADRD are measured to improve drug development and clinical care.

“Cogstate is a pioneer in the use of digital technologies to optimize the measurement of cognitive health in Alzheimer’s disease for the development of new medicines and for earlier and more accurate diagnosis in healthcare,” said Brad O’Connor, Cogstate CEO. “We are eager to work with DiMe and fellow project members to progress this important work in the fight against this devastating global public health crisis.”

“It is a pleasure to have Cogstate in our cohort of leading companies working to build consensus for a set of core digital measures for Alzheimer’s disease and related dementias,” said Christina Marasco, PhD, Program Lead, DiMe. “Bringing together this group is a tremendous opportunity to speed the development of effective new therapies and improve care management.”


About Cogstate

Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world. For more information, go to or follow us on LinkedIn and Twitter.



About the Digital Medicine Society

The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community, driving scientific progress and broad acceptance of digital medicine to enhance public health. At DiMe, our commitment to fully integrating experts from all of the disciplines comprising digital medicine is unwavering. From regulators to white-hat hackers, ethicists to engineers, and clinicians to citizen scientists, we are proud to welcome all experts committed to ensuring that digital medicine realizes its full potential to improve human health.


Back to News